Lipocine (LPCN) said Tuesday that it signed an exclusive supply and distribution agreement with Pharmalink to commercialize its Tlando oral testosterone replacement therapy in the Gulf Cooperation Council or GCC countries.

The company said it received an upfront payment from Pharmalink but did not disclose the amount. The company said it will supply Tlando to Pharmalink at an agreed price once it secures marketing authorizations in the GCC countries of the UAE, Saudi Arabia, Kuwait, Qatar, Bahrain, and Oman.

As part of the deal, Pharmalink will have exclusive rights to Tlando in the GCC countries, covering the product's promotion, distribution, and sale.

Price: 5.06, Change: +0.07, Percent Change: +1.40